

How to Order VYEPTI® (eptinezumab-jjmr)

Under the Medical Benefit

VYEPTI is the first IV-infused calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults.

Insurance verification

Verifying your patient's insurance will determine how VYEPTI will be obtained and administered. If your patient's insurance allows for VYEPTI to be **administered in office**, you may order through one of the authorized **specialty distributors** listed below.

If your patient's insurance requires that VYEPTI be obtained through a **specialty pharmacy**, you may contact one of the VYEPTI-approved specialty pharmacies to begin the ordering process.

VYEPTI National Drug Code

10-Digit Format	11-Digit Format for Claims Submission	HCPCS J-Code
100 mg/mL Solution in Single-dose Vial		
67386-130-51	67386-0130-51	J3032

Order through one of these authorized specialty distributors

ASD Healthcare (hospitals)	McKesson Plasma & Biologics (hospitals and alternate sites of care)
P: 800-746-6273 F: 800-547-9413	P: 877-625-2566 F: 888-752-7626
asdhealthcare.com/home	connect.mckesson.com
Besse Medical (physician offices and clinics)	McKesson Specialty Care Division (physician offices)
P: 800-543-2111 F: 800-543-8695	P: 855-477-9800 F: 800-800-5673
besse.com/home	mcs.mckesson.com
Oncology Supply (physician offices and clinics)	
P: 800-633-7555 F: 800-248-8205	
oncologysupply.com/contact	

Order through one of these approved specialty pharmacies

Orsini Healthcare	AllianceRx Walgreens Prime
P: 800-259-7145 F: 877-892-3019	P: 855-244-2555 F: 877-828-3939
orsinihealthcare.com/enrollment-forms	https://alliancerxwp.com/referral-forms

Lundbeck does not recommend the use of any particular specialty distributor or specialty pharmacy.

Below is a helpful checklist that your office can use when submitting a prescription to a specialty pharmacy.

Specialty pharmacy checklist

- Completed specialty pharmacy enrollment form, available at <https://www.orsinihealthcare.com/enrollment-forms> or <https://alliancerxwp.com/referral-forms>
- If not using a specialty pharmacy enrollment form, then please provide a complete prescription via fax or electronic medical record (EMR), including
 - Patient demographics
 - Patient's active medical and pharmacy insurance information and/or a copy of both insurance cards
 - Any clinical information on file

If your office has secured a PA prior to sending prescription to the specialty pharmacy, you may need to provide

- Prior authorization, which should include
 - J-code for VYEPTI (J3032)
 - The specialty pharmacy's name designated as the service provider

Important Safety Information

CONTRAINDICATIONS

- VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

Please see additional Important Safety Information on the next page.
For more information, click on [Prescribing Information](#) including [Patient Information](#) or visit vyeptihcp.com.



How VYEPTI is supplied

VYEPTI is supplied in a carton containing 1 single-dose vial. Each single-dose vial contains 100 mg in a 1 mL sterile, preservative-free solution. VYEPTI is a clear to slightly opalescent, colorless to brownish-yellow solution for dilution in a 100 mL bag of 0.9% Sodium Chloride Injection, USP, prior to intravenous infusion.

Storing and handling VYEPTI

Store refrigerated at 2°C to 8°C (36°F to 46°F) in original outer carton to protect from light until time of use. Do not freeze or shake.

Follow instructions in the Prescribing Information for dilution and storage and handling of diluted product.

For product-related questions, please contact Medical Information at 833-4-VYEPTI, option 5, Monday through Friday, 8 AM - 8 PM EST.

Indication

VYEPTI® is indicated for the preventive treatment of migraine in adults.

Important Safety Information

CONTRAINDICATIONS

- VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

WARNINGS AND PRECAUTIONS

- **Hypersensitivity reactions:** Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

ADVERSE REACTIONS

- The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, click on [Prescribing Information](#) including [Patient Information](#) or visit vyeptihcp.com.

For assistance with reimbursement questions,
contact your VYEPTI CONNECT Liaison at 833-4-VYEPTI,
Monday through Friday, 8 AM - 8 PM EST.



©2021 Lundbeck. All rights reserved.
VYEPTI and VYEPTI CONNECT are trademarks of
Lundbeck Seattle BioPharmaceuticals, Inc.
EPT-B-100512

